CTLA4 and metastatic melanoma: Ipilumumab, a monoclonal antibody against cytotoxic T lymphocyte antigen 4 (CTLA4), was approved in March 2011 and was the first immune checkpoint inhibitor to show an overall survival advantage in metastatic melanoma [17].